美国制药与生物技术：特朗普总统给制药业的最惠国待遇信函，更多是政治压力，而非引发更大担忧的事由-US Pharmaceuticals and Biotechnology_ President Trump‘s MFN letter to pharma appears more as political pressure than cause for increased concern

Flash | Geoff Meacham, Ph.D.AC +1-404-443-4701 geoffrey.meacham@citi.com 31 Jul 2025 14:48:47 ET │ 8 pages Jarwei Fang +1-212-816-3582 jarwei.fang@citi.com US Pharmaceuticals and Biotechnology President Trump's MFN letter to pharma appears more as political pressure than cause for increased concern CITI'S TAKE President Trump's letters (Bloomberg here, 7/31) sent to 17 of the largest Biopharmas seeking MFN pricing is likely to cause downward pressure on the DRG index. However, we caution against knee-jerk r ...